PBMs Archives - The Free Financial Advisor

The Co-Pay Shift: Why Major Insurers Updated Their Drug Tiers — Image Source: Unsplash.com

Rising prescription costs are forcing major health insurers to redraw the map on how medications get priced at the pharmacy counter. Suddenly, drugs that once sat comfortably in lower-cost tiers now sit higher, and that shift is shaking up budgets across households. These changes do not happen randomly, and they reflect deeper financial pressures inside the healthcare system. Pharmacy Benefit Managers, drug manufacturers, and insurers all play a role in how these tiers get built and adjusted. Patients now face a new reality where the same prescription can cost dramatically more from one year to the next.

At the center of this shift sits a mix of expensive specialty medications, growing demand for chronic disease treatments, and rapidly evolving drug innovation. Insurers now try to balance affordability for members with rising costs across the entire system.

Why Drug Tiers Keep Moving Around

Health insurers use drug tiers to organize medications based on cost and clinical value, but those categories rarely stay fixed for long. Rising drug prices push insurers to constantly reevaluate where each medication belongs within their formulary structure. Specialty medications, especially for conditions like autoimmune diseases or cancer, often drive the biggest cost spikes. When those costs rise, insurers shift placement to stabilize overall spending.

PBMs negotiate rebates and discounts behind the scenes, and those deals influence tier placement more than most people realize. If a manufacturer raises prices or changes rebate structures, insurers often respond by moving a drug into a higher tier. That move increases co-pays and shifts more cost responsibility to patients. These adjustments aim to keep premiums from rising too quickly, even if that creates frustration at the pharmacy counter.

Specialty Drugs and the Cost Pressure Cooker

Specialty drugs now dominate insurance spending in many plans, even though they serve smaller patient groups. Medications for conditions like multiple sclerosis, rheumatoid arthritis, and rare diseases often carry price tags that exceed thousands of dollars per month. Insurers cannot absorb those costs without making adjustments elsewhere in the system. That pressure leads to frequent reshuffling of tiers and stricter coverage rules.

Biologics and advanced therapies intensify this pressure because they often lack cheaper alternatives. Even when biosimilars enter the market, adoption takes time due to prescribing habits and patient stability concerns. Insurers respond by incentivizing biosimilar use through lower co-pays and preferred tier placement. These strategies aim to control spending while still keeping access open to necessary treatments.

The Hidden Role of Pharmacy Benefit Managers

PBMs act as intermediaries between insurers, drug manufacturers, and pharmacies, and they heavily influence how drug tiers take shape. They negotiate rebates that often determine whether a medication lands in a preferred or non-preferred tier. Those negotiations rarely stay visible to patients, yet they directly affect out-of-pocket costs. When rebate structures shift, insurers often respond by adjusting formularies mid-cycle or at renewal.

Conflicts of interest sometimes emerge because PBMs may prioritize higher rebate drugs even if cheaper alternatives exist. That dynamic can push certain medications into higher tiers despite similar clinical effectiveness. Patients then face higher co-pays unless doctors switch prescriptions or seek prior authorization. This system creates a ripple effect that reaches nearly every prescription filled at the pharmacy.

How Co-Pay Changes Hit Everyday Patients

A tier shift might look minor on paper, but it can dramatically change monthly budgets for people managing chronic conditions. A drug moving from a preferred tier to a higher tier can double or even triple co-pay costs overnight. Patients often discover these changes only when they arrive at the pharmacy counter, creating frustration and confusion. These surprises can lead to skipped doses or delayed refills when budgets cannot stretch further.

Doctors often step in by switching prescriptions or submitting prior authorization requests to reduce patient costs. However, those processes take time and sometimes delay treatment access. Patients managing multiple medications feel the impact even more sharply because several small increases add up quickly. The co-pay shift often forces families to reassess how they prioritize healthcare spending.

Why Insurers Say These Changes Protect Long-Term Affordability

Insurers argue that tier restructuring helps keep overall premiums lower by distributing costs more strategically. Without these adjustments, rising drug prices would push insurance premiums higher for everyone in the plan. By shifting more cost responsibility to higher tiers, insurers attempt to preserve affordability for generic and essential medications. This approach tries to balance individual impact with system-wide sustainability.

Critics argue that this strategy places too much burden on patients who rely on expensive medications. They point out that affordability at the pharmacy counter matters just as much as monthly premiums. Still, insurers continue refining these structures as drug prices and market dynamics evolve. The result creates a constant push and pull between cost control and patient access.

What This Shift Signals About the Future of Prescription Costs

Drug tier changes reflect a healthcare system under constant financial strain, where innovation and affordability often collide. As more high-cost therapies enter the market, insurers will likely continue adjusting co-pays and coverage rules. Patients may see more variability in costs from year to year, even for the same medication. That unpredictability makes budgeting for healthcare increasingly challenging.

The co-pay shift shows how quickly prescription costs can change when insurers, drug makers, and PBMs adjust their strategies behind the scenes. Staying informed helps patients anticipate changes before they hit the pharmacy counter and disrupt monthly budgets.

How do you think insurers should balance rising drug costs with patient affordability at the pharmacy?

1. The Shocking Price Gap Between America and the World

Americans pay 2-6 times more for prescription drugs than citizens of other developed nations. A month’s supply of Humira, used to treat conditions like rheumatoid arthritis, costs approximately $5,800 in the U.S. but only $1,400 in the UK. This isn’t because drugs cost more to produce or distribute in America—it’s because the U.S. lacks the price negotiation mechanisms that exist in countries with universal healthcare systems.

Unlike most developed nations, Medicare was legally prohibited from negotiating drug prices until the recent Inflation Reduction Act, which only allows negotiation for a limited number of drugs starting in 2026. This restriction has allowed pharmaceutical companies to set prices at whatever the market will bear, regardless of actual value or development costs.

2. The Patent Game That Keeps Generics Off the Market

Pharmaceutical companies employ a strategy called “evergreening” to extend patent protections far beyond the intended 20-year period. Companies can secure new patents that block generic competition by making minor modifications to existing drugs—changing the coating, delivery method, or combining with another medication. AbbVie, Humira’s manufacturer, obtained over 130 patents to protect its blockbuster drug, extending market exclusivity for 20 years beyond the original patent.

This practice, known as “patent thicketing,” creates legal obstacles that are too expensive for generic manufacturers to fight. According to a study in the Journal of Law and the Biosciences, 78% of drugs associated with new patents between 2005 and 2015 were existing drugs, not new medications.

3. The Middlemen Making Billions Off Your Prescriptions

Pharmacy Benefit Managers (PBMs) were originally created to help insurers negotiate better drug prices. Today, these middlemen have become powerful entities that often increase costs rather than reduce them. The three largest PBMs—CVS Caremark, Express Scripts, and OptumRx—control approximately 80% of the market.

They negotiate rebates from drug manufacturers but rarely pass the full savings to consumers. Instead, they create complex formularies that favor high-priced drugs with larger rebates, which increases their profit margins while patients pay more at the pharmacy counter. This opaque system makes it nearly impossible to determine the actual cost of medications and who benefits from the various transactions.

4. The Insurance Trap That Leaves Patients Vulnerable

Even with insurance, many Americans face substantial out-of-pocket costs for prescription medications. High-deductible health plans require patients to pay thousands before coverage kicks in, while coinsurance percentages rather than fixed copays expose patients to price increases.

A Kaiser Family Foundation survey found that 29% of American adults report not taking medications as prescribed due to cost. This medication non-adherence leads to approximately 125,000 deaths annually and costs the healthcare system between $100-289 billion in additional medical expenses. Insurance designs that shift costs to patients create a dangerous cycle where people ration essential medications, leading to worse health outcomes and higher long-term costs.

5. The Direct-to-Consumer Advertising That Drives Up Costs

The United States and New Zealand are the only developed nations that allow direct-to-consumer pharmaceutical advertising. These marketing campaigns cost pharmaceutical companies billions annually, costs that are ultimately passed on to consumers through higher drug prices. In 2020 alone, pharmaceutical companies spent $6.58 billion on advertising, creating demand for newer, more expensive medications even when equally effective and cheaper alternatives exist.

These advertisements rarely mention price and often downplay side effects while emphasizing benefits, leading patients to request specific brand-name drugs from their doctors. This marketing-driven demand contributes significantly to America’s prescription drug spending, which reached $576 billion in 2021.

6. The Real Solutions Being Blocked by Industry Influence

Pharmaceutical industry lobbying has effectively blocked many potential solutions to the prescription pricing scandal. The industry spent $306 million on lobbying in 2020 alone, employing over 1,500 lobbyists—more than two for every member of Congress. This influence has prevented meaningful reforms like allowing Medicare to negotiate all drug prices, permitting prescription importation from Canada, and reforming patent laws to prevent evergreening.

Several states have attempted to implement transparency laws and price controls, but industry lawsuits have delayed or weakened many of these efforts. The pharmaceutical industry’s political influence ensures that even popular, bipartisan solutions face significant obstacles to implementation.

The Path Forward: Taking Control of Your Medication Costs

Despite systemic challenges, individuals can take steps to reduce their prescription costs. Always ask your doctor about generic alternatives, which typically cost 80-85% less than brand-name medications. Utilize prescription discount cards and programs like GoodRx or RxSaver, which sometimes offer lower prices than insurance copays.

For expensive medications, investigate patient assistance programs offered by pharmaceutical manufacturers. Consider therapeutic alternatives in the same drug class that may be less expensive but equally effective. Most importantly, become an informed advocate—understand your insurance coverage, question high prices, and support policy reforms to make medications more affordable.

Have you ever had to make difficult financial decisions because of prescription drug costs? Share your experience in the comments below, and any strategies you’ve found helpful in managing medication expenses.

7 Cunning Ways Nursing Homes Can Drain Your Life Savings

Travis Campbell

Travis Campbell is a digital marketer/developer with over 10 years of experience and a writer for over 6 years. He holds a degree in E-commerce and likes to share life advice he’s learned over the years. Travis loves spending time on the golf course or at the gym when he’s not working.

The Co-Pay Shift: Why Major Insurers Updated Their Drug Tiers